Multiple Myeloma: International Myeloma Foundation : •treatment options : imf research grants archive : Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma

imf research grants archive

back

Development of the antihelmintic flubendazole as a novel therapeutic agent for the treatment of multiple myeloma

Aaron Schimmer, MD, PhD, FRCPC
Princess Margaret Hospital
Ontario Cancer Institute
Toronto, ON, Canada

	02.03.10
Be the first to comment Name Email Address URL Remember personal info? Comments (You may use HTML tags for style)	print share \| related articles Bone marrow microenv... Characterization and... Mesenchymal cell cyt... MMSET and epigenetic... Novel anti-myeloma t... Reolysin: a novel re...

Bone marrow microenvironment and multiple myeloma chemotherapy optimization

Characterization and preclinical evaluation of NKT cells in multiple myeloma

Mesenchymal cell cytotherapy for multiple myeloma

MMSET and epigenetic control in t(4;14) myelomas

Novel anti-myeloma therapy by targeting molecular signaling regulated by galectin family proteins

Reolysin: a novel reovirus-based therapy for multiple myeloma

Be the first to comment